Welcome to our dedicated page for KMPH news (Ticker: KMPH), a resource for investors and traders seeking the latest updates and insights on KMPH stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect KMPH's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of KMPH's position in the market.
KemPharm (NASDAQ: KMPH) reported significant milestones, including the FDA approval of AZSTARYS on March 2, 2021, and completion of financial restructuring, leading to a debt-free status. For Q4 2020, revenue was $2.4 million, an increase from $1.9 million in Q3 2020, while the net loss decreased to ($4.9 million) from ($6.0 million) in Q4 2019. The full-year revenue reached $13.3 million compared to $12.8 million in 2019, with total cash of $77.6 million as of March 10, 2021. Upcoming clinical trials for KP879 are anticipated to enhance the company’s growth potential.
KemPharm, Inc. (NASDAQ: KMPH) has reported significant developments in its recent press release. The FDA approved the NDA for AZSTARYS on March 2, 2021, and the company restructured its financials to eliminate debt and raise approximately $94 million. Q4 2020 revenue was $2.4 million, with a reduced net loss of ($4.9 million) compared to Q4 2019. KemPharm is now positioned for growth with a strong cash position of $77.6 million as of March 10, 2021, and plans to initiate KP879’s clinical program for Stimulant Use Disorder in 2021.
KemPharm, Inc. (NASDAQ: KMPH) will host a conference call and live audio webcast on March 11, 2021, at 4:30 p.m. ET, to discuss financial results for Q4 and the full year 2020. The event will feature a slide presentation accessible on the company's Investor Relations website. KemPharm's product portfolio includes AZSTARYS™, an FDA-approved ADHD treatment, and its pipeline features candidates like KP484 and KP879 focusing on ADHD and Stimulant Use Disorder.
KemPharm, Inc. (NASDAQ: KMPH) announced a conference call and live audio webcast set for March 11, 2021, at 4:30 p.m. ET. This event will discuss the corporate and financial results for Q4 and full year 2020. Participants can join via phone or webcast, with an archived presentation available for 90 days post-event. KemPharm focuses on developing proprietary prodrugs, particularly AZSTARYS™, an FDA-approved ADHD treatment. The company also advances other candidates such as KP484 and KP879, showcasing its commitment to addressing serious medical conditions.
KemPharm, a specialty pharmaceutical company, announced that President and CEO Travis C. Mickle, Ph.D., will present at the 33rd Annual Roth Conference from March 15-17, 2021. The presentation will be available on demand for registered attendees. Dr. Mickle will discuss KemPharm’s achievements and milestones, including the FDA approval of AZSTARYS™, a once-daily ADHD treatment for patients aged six and older. AZSTARYS combines serdexmethylphenidate with immediate-release d-MPH. For registration details, visit the Roth Conference website.
KemPharm, a specialty pharmaceutical company, announces that its President and CEO, Travis C. Mickle, Ph.D., will present at the 33rd Annual Roth Conference from March 15-17, 2021. The presentation will be available on demand for registered attendees. Dr. Mickle will highlight KemPharm's recent achievements, including the FDA approval of AZSTARYS™, a once-daily ADHD treatment for patients aged six and older. AZSTARYS combines serdexmethylphenidate (SDX) with immediate-release d-MPH. For more details, visit kempharm.com.
KemPharm, Inc. (NASDAQ: KMPH) announced FDA approval for its new drug AZSTARYS™, a treatment for ADHD in patients aged six and older. The product, combining serdexmethylphenidate and d-methylphenidate, is set for commercial availability in the U.S. by the second half of 2021, led by Corium, Inc. KemPharm may receive up to $468 million in milestone payments under a licensing agreement. This approval is seen as a significant advancement in ADHD treatment, addressing unmet needs in the market, which totaled approximately $17.9 billion in 2019.
KemPharm, Inc. (NASDAQ: KMPH) announced FDA approval for AZSTARYS™, a once-daily ADHD treatment for patients aged six and older. AZSTARYS combines serdexmethylphenidate (SDX) and immediate-release d-methylphenidate. Corium, a Gurnet Point Capital affiliate, will commercialize the product, expected in the U.S. by the second half of 2021. KemPharm stands to gain up to $468 million in milestone payments and royalties under its agreement with GPC. The ADHD market generated approximately $17.9 billion in revenue in 2019, indicating significant commercial potential for AZSTARYS.
KemPharm, Inc. (NASDAQ: KMPH) announced the FDA's approval of its IND application for KP879, allowing the commencement of its clinical program in 2021. KP879 aims to treat Stimulant Use Disorder using serdexmethylphenidate. The company has also completed a financial restructuring, addressing its $93.1 million debt, and has regained its Nasdaq listing. Recent successful transactions yielded gross proceeds of approximately $94 million, bolstering KemPharm's financial position and ultimately enhancing shareholder value.
KemPharm, Inc. (NASDAQ: KMPH) announced that research on its ADHD treatment, KP415, will be presented at the 2021 APSARD Virtual Conference from January 15-17, 2021. The NDA for KP415 is under FDA review, with a PDUFA date set for March 2, 2021. Highlights include an oral symposium on the lower abuse potential of serdexmethylphenidate (SDX) and three poster presentations detailing KP415's efficacy, safety, and tolerability in children aged 6-12. The data emphasizes KP415's potential to meet unmet needs in ADHD treatment.
FAQ
What is the market cap of KMPH (KMPH)?
